drugset
drugset / Trial / NCT06614270

Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases

NCT06614270 ↗

Recruiting 15 enrolled Second Affiliated Hospital, School of Medicine, Zhejiang University
NaSingle-groupOpen-labelTreatment

Summary

This study is a single-center, open-label, single-arm, dose-escalation trial. The aim of this study is to investigate the safety and efficacy of Anti-CD19 IL-10/IL15 CAR-NK cells in patients with refractory/relapsed autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myositis, ANCA associated vasculitis, sjogren syndrome, and antiphospholipid syndrome.

Timeline

Start
2025-01-06
Primary completion
2026-01-06
Completion
2027-01-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Anti-CD19 IL-10/IL15 CAR-NK Cell therapy — —
Background Cyclophosphamide Other / unclassified — —
Background Fludarabine Small molecule — —

Indications

Sjogren syndrome anti-neutrophil cytoplasmic antibody-associated vasculitis antiphospholipid syndrome idiopathic inflammatory myopathy systemic lupus erythematosus systemic sclerosis